Recent Progress of Studies on Endogenous Angiogenesis Inhibitive Factors and Their Possible Effect in Therapy of Hepatocarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Jingyu , HE Sheng.

Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

Endogenous angiogenesis inhibitive factor Tumor Endothelial inhibitor Vascular inhibitor Hepatocarcinoma

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】Objective To introduce the possible effect of endogenous angiogenesis inhibitive factors in the therapy of hepatocarcinoma.
Methods Recent relevant literatures were reviewed.
ResultsEndogenous angiogenesis inhibitive factors can suppress the growth of tumor blood vessels, which might head off the development and metastasis of hepatocarcinoma effectively. This might provide a new approach to the therapy of hepatocarcinoma.
ConclusionRecent studies on endogenous angiogenesis inhibitive factors will be helpful in the prevention and treatment of hepatocarcinoma.

Citation： DENG Jingyu,HE Sheng.. Recent Progress of Studies on Endogenous Angiogenesis Inhibitive Factors and Their Possible Effect in Therapy of Hepatocarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2006, 13(2): 184-186. doi: Copy

1.	Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971; 285(21)∶1182.
2.	Yancopoulos GD, Davis S, Gale NW, et al. Vascularspecific growth factors and blood vessel formation [J]. Nature, 2000; 407(6801)∶242.
3.	Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J]. Cell, 1996; 86(3)∶353.
4.	Iwasaki T, Hamano T, Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma [J]. Br J Haematol, 2002; 116(4)∶796.
5.	侯恩存. 肿瘤血管生成与抗血管生成治疗 [J]. 中国肿瘤临床与康复， 2003； 10（2）∶179.
6.	过邦辅，凌励立. 血管生成和蛋白酶在肿瘤侵袭中的作用 [J]. 中国肿瘤， 1999； 8（4）∶177.
7.	王成伟，宠琦，张庆林. 血管生成与肿瘤的生长及转移 [J]. 国外医学·肿瘤学分册， 2001； 28（2）∶118.
8.	Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
9.	骆成玉，祝学光. 肿瘤血管生成对微转移影响的研究进展 [J]. 中国普外基础与临床杂志， 2003； 10（5）∶516.
10.	Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin [J]. Cell Growth Differ, 1998; 9(4)∶305.
11.	Folkman J. What is the evidence that tumors are angiogenesis dependent? [J]. J Natl Cancer Inst, 1990; 82(1)∶4.
12.	颜春洪，韩锐. 抗恶性肿瘤转移药研究进展 [A]. 见：曹世龙主编.肿瘤学新理论与新技术 [M]. 上海：上海科技教育出版社， 1997∶462～484.
13.	Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis [J]. Cancer Metastasis Rev, 1996; 15(2)∶165.
14.	Merwin RM, Algire GH. The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue [J]. J Natl Cancer Inst, 1956; 17(1)∶23.
15.	Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis [J]. Nature, 1982; 297(5864)∶307.
16.	后信，桑野信彦. か转移阻止开发口一千 [J]. 日本癌症治疗， 1995； 30（5）∶713.
17.	Saphir A. Angiogenesis: the unifying concept in cancer? [J]. J Natl Cancer Inst, 1997; 89(22)∶1658.
18.	Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy [J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶155.
19.	王贵齐. 肿瘤与血管 [J]. 中国肿瘤临床， 1995； 22（10）∶743.
20.	Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells [J]. J Biol Chem, 1996; 271(46)∶29461.
21.	Cao Y, Chen A, An SS, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth [J]. J Biol Chem, 1997; 272(36)∶22924.
22.	Luo J, Lin J, Paranya G, et al. Angiostatin upregulates Eselectin in proliferating endothelial cells [J]. Biochem Biophys Res Commun, 1998; 245(3)∶906.
23.	Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin [J]. Cancer Res, 1999; 59(23)∶5875.
24.	Standker L, Schrader M, Kanse SM, et al. Isolation and characterization of the circulating form of human endostatin [J]. FEBS Lett, 1997; 420(2-3)∶129.
25.	Schuppan D, Cramer T, Bauer M, et al. Hepatocytes as a source of collagen type ⅩⅧ endostatin [J]. Lancet, 1998; 352(9131)∶879.
26.	He ZY, Chen ZY, Qiu CP, et al. Cloning, expression and tamor suppression of human endostatin [J]. Acta Biochemica and Biophysica Sinica, 2000; 32(4)∶333.
27.	Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen ⅩⅧ [J]. EMBO J, 2000; 19(6)∶1187.
28.	王轩，刘福坤，黎介寿. 血管内皮抑制素的研究进展 [J]. 临床肿瘤学杂志， 2001； 6（3）∶287.
29.	Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis [J]. Blood, 2000; 95(11)∶3403.
30.	Yamaguchi N, AnandApte B, Lee M, et al. Endostatin inhibits VEGFinduced endothelial cell migration and tumor growth independently of zinc binding [J]. EMBO J, 1999; 18(16)∶4414.
31.	Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin [J]. Biochem Biophys Res Commun, 1999; 258(2)∶345.
32.	Hohenester E, Sasaki T, Mann K, et al. Variable zinc coordination in endostatin [J]. J Mol Biol, 2000; 297(1)∶1.
33.	Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors [J]. Cancer Res, 2000; 60(7)∶1793.
34.	孙惠川，汤钊猷，王鲁. Endostatin抑制裸鼠移植性肝癌切除后的复发移植 [J]. 中华肿瘤杂志， 2000； 22（6）∶469.
35.	Folkman J. Antiangiogenic gene therapy [J]. Proc Natl Acad Sci USA， 1998; 95(16)∶9064.
36.	Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents [J]. Int J Cancer, 1994; 57(6)∶920.

1. Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971; 285(21)∶1182.
2. Yancopoulos GD, Davis S, Gale NW, et al. Vascularspecific growth factors and blood vessel formation [J]. Nature, 2000; 407(6801)∶242.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J]. Cell, 1996; 86(3)∶353.
4. Iwasaki T, Hamano T, Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma [J]. Br J Haematol, 2002; 116(4)∶796.
5. 侯恩存. 肿瘤血管生成与抗血管生成治疗 [J]. 中国肿瘤临床与康复， 2003； 10（2）∶179.
6. 过邦辅，凌励立. 血管生成和蛋白酶在肿瘤侵袭中的作用 [J]. 中国肿瘤， 1999； 8（4）∶177.
7. 王成伟，宠琦，张庆林. 血管生成与肿瘤的生长及转移 [J]. 国外医学·肿瘤学分册， 2001； 28（2）∶118.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995; 1(1)∶27.
9. 骆成玉，祝学光. 肿瘤血管生成对微转移影响的研究进展 [J]. 中国普外基础与临床杂志， 2003； 10（5）∶516.
10. Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin [J]. Cell Growth Differ, 1998; 9(4)∶305.
11. Folkman J. What is the evidence that tumors are angiogenesis dependent? [J]. J Natl Cancer Inst, 1990; 82(1)∶4.
12. 颜春洪，韩锐. 抗恶性肿瘤转移药研究进展 [A]. 见：曹世龙主编.肿瘤学新理论与新技术 [M]. 上海：上海科技教育出版社， 1997∶462～484.
13. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis [J]. Cancer Metastasis Rev, 1996; 15(2)∶165.
14. Merwin RM, Algire GH. The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue [J]. J Natl Cancer Inst, 1956; 17(1)∶23.
15. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis [J]. Nature, 1982; 297(5864)∶307.
16. 后信，桑野信彦. か转移阻止开发口一千 [J]. 日本癌症治疗， 1995； 30（5）∶713.
17. Saphir A. Angiogenesis: the unifying concept in cancer? [J]. J Natl Cancer Inst, 1997; 89(22)∶1658.
18. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy [J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶155.
19. 王贵齐. 肿瘤与血管 [J]. 中国肿瘤临床， 1995； 22（10）∶743.
20. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells [J]. J Biol Chem, 1996; 271(46)∶29461.
21. Cao Y, Chen A, An SS, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth [J]. J Biol Chem, 1997; 272(36)∶22924.
22. Luo J, Lin J, Paranya G, et al. Angiostatin upregulates Eselectin in proliferating endothelial cells [J]. Biochem Biophys Res Commun, 1998; 245(3)∶906.
23. Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin [J]. Cancer Res, 1999; 59(23)∶5875.
24. Standker L, Schrader M, Kanse SM, et al. Isolation and characterization of the circulating form of human endostatin [J]. FEBS Lett, 1997; 420(2-3)∶129.
25. Schuppan D, Cramer T, Bauer M, et al. Hepatocytes as a source of collagen type ⅩⅧ endostatin [J]. Lancet, 1998; 352(9131)∶879.
26. He ZY, Chen ZY, Qiu CP, et al. Cloning, expression and tamor suppression of human endostatin [J]. Acta Biochemica and Biophysica Sinica, 2000; 32(4)∶333.
27. Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen ⅩⅧ [J]. EMBO J, 2000; 19(6)∶1187.
28. 王轩，刘福坤，黎介寿. 血管内皮抑制素的研究进展 [J]. 临床肿瘤学杂志， 2001； 6（3）∶287.
29. Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis [J]. Blood, 2000; 95(11)∶3403.
30. Yamaguchi N, AnandApte B, Lee M, et al. Endostatin inhibits VEGFinduced endothelial cell migration and tumor growth independently of zinc binding [J]. EMBO J, 1999; 18(16)∶4414.
31. Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin [J]. Biochem Biophys Res Commun, 1999; 258(2)∶345.
32. Hohenester E, Sasaki T, Mann K, et al. Variable zinc coordination in endostatin [J]. J Mol Biol, 2000; 297(1)∶1.
33. Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors [J]. Cancer Res, 2000; 60(7)∶1793.
34. 孙惠川，汤钊猷，王鲁. Endostatin抑制裸鼠移植性肝癌切除后的复发移植 [J]. 中华肿瘤杂志， 2000； 22（6）∶469.
35. Folkman J. Antiangiogenic gene therapy [J]. Proc Natl Acad Sci USA， 1998; 95(16)∶9064.
36. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP470 alone and with other antiangiogenic agents [J]. Int J Cancer, 1994; 57(6)∶920.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Recent Progress of Studies on Endogenous Angiogenesis Inhibitive Factors and Their Possible Effect in Therapy of Hepatocarcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content